Of the many challenges that Synthetic Biology (SynBio) companies and BioFoundries currently face is predictive scale-up - from lab to production – which is an important and essential step in the process. Transitioning from a lab-scale shake flask to a GMP manufacturing process is a daunting task that involves multiple steps and models to get there.

So how do SynBio start-ups or BioFoundries address this? What happens after the DBTL cycle ends? Is scalability and manufacturability factored into the initial design process (‘design with the end in mind’) or is it addressed afterwards? What role can the suppliers play in this? How are they tackling the scale-up/manufacturability issue? Is SynBio delivering on its promise? What direction are we heading in the near-future (synthetic cells, CFS)?

In this event, we will hear from some of the most exciting innovators in the field and discuss how the industry is innovating in order to facilitate rapid and predictable scale-up.

The Speakers:

Ted Fjällman, CEO - Prokarium

Edward Green, CEO - Chain Biotech

Michael Sulu, Research Associate - UCL Department of Biochemical Engineering

Fane Mensah, Head of scientific community CAB - Synthace

Agenda:

17.30-18.00 Campus tour (optional) Register here

18.00-18.30 Registration

18.30-18.50 Intro by Sartorius

18.50-19.10 Presentations

19.10-20.00 Fireside Chat

20.00-20.45 Networking

_______________

Central Working`

Generously hosted by Central Working, the UK’s premier homegrown shared workspace provider, transforming the way people work and companies grow.

‍